sacituzumab govitecan

FDA uncovers data manipulation at Immunomedics plant making cancer drug
FDA uncovers data manipulation at Immunomedics plant making cancer drug
Fierce Pharma
FDS
Immunomedics
sacituzumab govitecan
drug manufacturing
Flag link:
Immunomedics, still searching for first approval, discloses forthcoming FDA re-inspection
Immunomedics, still searching for first approval, discloses forthcoming FDA re-inspection
Biopharma Dive
Immunomedics
FDA
sacituzumab govitecan
Flag link:
FDA rejects Immunomedics breast cancer drug, extending long regulatory drought
FDA rejects Immunomedics breast cancer drug, extending long regulatory drought
Stat
Immunomedics
FDA
breast cancer
sacituzumab govitecan
Flag link:
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
CP Wire
Immunomedics
FDA
sacituzumab govitecan
triple negative breast cancer
Flag link:
Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today
Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today
Motley Fool
Immunomedics
ASCO 2018
sacituzumab govitecan
breast cancer
Flag link:
6 Key Cancer Winners From ASCO Presentations
6 Key Cancer Winners From ASCO Presentations
24/7 Wall St
ASCO
Immunogen
mirevtuximab soravtansine
ONT-380
Oncothyreon
cabozantinib
Exelixis
VB-111
Vascular Biogenics
Immunomedics
sacituzumab govitecan
pacritinib
CTI BioPharma
Flag link:
Patients With Advanced Breast, Lung, Esophageal, and Colorectal Cancers Respond to Immunomedics' Novel Antibody-Directed Chemotherapy After Failing Multiple Prior Standard Treatments
Patients With Advanced Breast, Lung, Esophageal, and Colorectal Cancers Respond to Immunomedics' Novel Antibody-Directed Chemotherapy After Failing Multiple Prior Standard Treatments
Yahoo
Immunomedics
chemotherapy
breast cancer
lung cancer
esophageal cancer
colorectal cancer
sacituzumab govitecan
Flag link: